Neuphoria TherapeuticsNEUP -19.32%32 EV-to-FCF is 0.01 as of Jul. 01, 2026. GuruFocus rates NEUP with a GF Score™ of 32/100. The stock has 1 warning sign investors should review. Among 331 Biotechnology companies, Neuphoria Therapeutics ranks worse than 302114.5% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Neuphoria Therapeutics's Enterprise Value is $-0.22 Mil.
Neuphoria Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $-17.15 Mil. Therefore, Neuphoria Therapeutics's EV-to-FCF for today is 0.01.
The historical rank and industry rank for Neuphoria Therapeutics's EV-to-FCF or its related term are showing as below:
NEUP'
s EV-to-FCF Range Over the Past 10 Years
Min: -12.93 Med: -0.26 Max: 138.57
Current: 0.01
During the past 13 years, the highest EV-to-FCF of Neuphoria Therapeutics was 138.57. The lowest was -12.93. And the median was -0.26.
NEUP's EV-to-FCF is not ranked
in the Biotechnology industry.
Industry Median: 15.9
vs NEUP: 0.01
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Neuphoria Therapeutics's PE Ratio (TTM) for today is calculated as:
Neuphoria Therapeutics's share price for today is $3.55.
Neuphoria Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-11.060.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Neuphoria Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neuphoria Therapeutics EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Neuphoria Therapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Neuphoria Therapeutics's EV-to-FCF falls into.
Neuphoria Therapeutics's current Enterprise Value is $-0.22 Mil.
Neuphoria Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-17.15 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neuphoria Therapeutics (NEUP) has a EV-to-FCF of 0.01 as of Jul. 01, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Neuphoria Therapeutics and its competitors. According to the industry distribution chart, Neuphoria Therapeutics ranks #999999 out of 331 companies in the Biotechnology industry.
Is Neuphoria Therapeutics' EV-to-FCF too high?
Neuphoria Therapeutics' current EV-to-FCF is 0.01. The Biotechnology industry median EV-to-FCF is 15.90. Neuphoria Therapeutics' value of 0.01 is 99.9% below this industry median. Based on the distribution chart, Neuphoria Therapeutics ranks #999999 out of 331 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Neuphoria Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Neuphoria Therapeutics' EV-to-FCF compare to PLRZ and SKYE?
According to the Biotechnology industry distribution chart, Neuphoria Therapeutics ranks #999999 out of 331 companies for EV-to-FCF. This places Neuphoria Therapeutics in the lower half of its industry. The industry median EV-to-FCF is 15.90. Neuphoria Therapeutics' value of 0.01 is 99.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 15.90, based on 331 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Neuphoria Therapeutics's current EV-to-FCF of 0.01 is 99.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Neuphoria Therapeutics and its competitors. For the Biotechnology industry, the median EV-to-FCF is 15.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Neuphoria Therapeutics's current EV-to-FCF is 0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neuphoria Therapeutics stock overvalued right now?
Neuphoria Therapeutics (NEUP) has a current EV-to-FCF of 0.01. The current EV-to-FCF is 0.01 and 99.9% below the Biotechnology industry median of 15.90. Neuphoria Therapeutics' overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Neuphoria Therapeutics (NEUP), the current EV-to-FCF is 0.01 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.
32GF Score
Get the complete analysis for NEUP
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NEUP has been successfully added to your 
